Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q92826
UPID:
HXB13_HUMAN
Alternative names:
-
Alternative UPACC:
Q92826; B2R878; Q96QM4; Q99810
Background:
Homeobox protein Hox-B13 plays a pivotal role in the developmental regulatory system, providing cells with specific positional identities along the anterior-posterior axis. Its ability to bind preferentially to methylated DNA underscores its significance in gene expression modulation.
Therapeutic significance:
Given its association with prostate cancer, particularly in influencing disease susceptibility through genetic variants, Homeobox protein Hox-B13 represents a critical target for therapeutic intervention. Understanding its role could lead to groundbreaking treatments for prostate cancer.